The Company leases its office facilities, located in Concord, California and Amersfoort, the Netherlands, and certain equipment and automobiles under non-cancelable operating leases with initial terms in excess of one year that require the Company to pay operating costs, property taxes, insurance and maintenance. The operating leases expire at various dates through 2030, with certain of the leases providing for renewal options, provisions for adjusting future lease payments based on the consumer price index, and the right to terminate the lease early. The Company does not assume renewals in determination of the lease term unless the renewals are deemed to be reasonably assured at lease commencement. The Company recorded the lease right-of-use asset and obligation at the present value of lease payments over the lease term. The rates implicit in the Company’s leases are generally not readily determinable. The Company must estimate its incremental borrowing rate to discount the lease payments to present value. Operating lease assets also include lease incentives.

Supplemental cash flow information related to operating leases is as follows (dollars in thousands):

	Year Ended
	December 31, 2020
Cash payments for operating leases	$	3,400
Right-of-use assets obtained in exchange for operating lease obligations		344

	December 31, 2020
Weighted-average remaining lease term	8.5 years
Weighted-average discount rate		9.0	%

Future minimum non-cancelable payments under operating leases as of December 31, 2020, were as follows (in thousands):

	Operating Leases
2021	$	3,535
2022		3,008
2023		2,840
2024		2,735
2025		2,716
Thereafter		13,337
Total future lease payments		28,171
Less imputed interest		9,383
Present value of lease liabilities	$	18,788

During the years ended December 31, 2020, 2019 and 2018, the Company recorded operating lease expenses of $3.3 million, $3.4 million and $1.6 million, respectively. As of December 31, 2020, the Company had no leases that have not yet commenced.

The Company is party to agreements with certain providers for certain components of the INTERCEPT Blood System. Certain of these agreements require minimum purchase commitments from the Company. As of December 31, 2020, the Company had $28.9 million of short-term purchase commitments and $4.0 million of long-term purchase commitments, which are not recorded in the Company’s consolidated balance sheets.